ArticleDrugs in context2018
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications.
Article in Drugs in context, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: A Bayesian network meta-regression analysis.Frontiers in oncology · 2023Pooled it
- The Role of Chemokine Receptor CXCR3 and Its Ligands in Renal Cell Carcinoma.International journal of molecular sciences · 2020Pooled it
- A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss.Molecular diagnosis & therapy · 2019Pooled it
- Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma.British journal of cancer · 2021Trial
- Article
- Cancer Immunotherapies: Navigating the Immune Landscape.Current cancer drug targets · 2026Review
- Photothermal-triggered non-apoptotic regulated cell death-related pathway regulation boosts systemic antitumor immunity.Materials today. Bio · 2025Article
- ANGPTL4 Suppresses Clear Cell Renal Cell Carcinoma via Inhibition of Lysosomal Acid Lipase.Cancer research communications · 2024Article
- Metabolite profiling of human renal cell carcinoma reveals tissue-origin dominance in nutrient availability.eLife · 2024Article
- Identification of novel snoRNA-based biomarkers for clear cell renal cell carcinoma from urine-derived extracellular vesicles.Biology direct · 2024Article
- Metabolite profiling of human renal cell carcinoma reveals tissue-origin dominance in nutrient availability.bioRxiv : the preprint server for biology · 2024Article
- SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Molecular Targets of Shenqi Dihuang, A Traditional Chinese Herbal Medicine, and Its Potential Role in Renal Cell Carcinoma Therapy.Genetics research · 2023Article
- ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- The integrated landscape of eRNA in gastric cancer reveals distinct immune subtypes with prognostic and therapeutic relevance.iScience · 2022Article
- Renal Cell Carcinoma Associated With HIV/AIDS: A Review of the Epidemiology, Risk Factors, Diagnosis, and Treatment.Frontiers in oncology · 2022Review
- The role of gut microbiome in immune modulation in metastatic renal cell carcinoma.Therapeutic advances in medical oncology · 2022Review
- Use of Circular RNAs in Diagnosis, Prognosis and Therapeutics of Renal Cell Carcinoma.Frontiers in cell and developmental biology · 2022Review
- Models of Renal Cell Carcinoma Used to Investigate Molecular Mechanisms and Develop New Therapeutics.Frontiers in oncology · 2022Review
- Development of a Novel Immune Subtyping System Expanded with Immune Landscape and an 11-Gene Signature for Predicting Prostate Cancer Survival.Journal of oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in understanding the mechanisms of tumour-induced immunosuppression have led to the development of immune-checkpoint inhibitors in cancer patients, including those with renal cell carcinoma (RCC). The optimal combination between immunotherapy and targeted agents (as well as the possible favourable sequential therapy of these two classes of drugs) remains an open question at this moment. Several trials are currently underway to assess the combination of anti-programmed-death 1 (PD-1) or anti-PD-ligand(L)1 agents with other immunotherapies or with anti-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). In this editorial, we described the results of the most recent clinical trials on the use of immunotherapies in RCC and the emerging data on the research for reliable biomarkers of tumour response in this setting. In addition, we have focused on the role of the gut microbiome and tumour microenvironment in the development of future therapeutic strategies for RCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.